BiotechTube

ramosetron + ondansetron

Phase 3UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer

Conditions

Cancer, Malignancy

Trial Timeline

Jun 1, 2011 → Feb 1, 2013

NCT ID
NCT01536691

About ramosetron + ondansetron

ramosetron + ondansetron is a phase 3 stage product being developed by Astellas Pharma for Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT01536691. Target conditions include Cancer, Malignancy.

What happened to similar drugs?

20 of 20 similar drugs in Cancer were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01536691Phase 3UNKNOWN

Competing Products

20 competing products in Cancer

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
E7389EisaiPhase 1
29
VeliparibAbbViePhase 2
27
AK-105AkesoPhase 1
29
XL820ExelixisPhase 1
26
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
pemetrexedEli LillyPhase 2
27
LY3300054 + PrexasertibEli LillyPhase 1
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
35
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35